Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 91 record(s)

Req # A-2020-000459

Adverse Drug Reaction (ADR) for Botulinum toxin. Report number: E2B_03031904.

Organization: Health Canada

13 page(s)
February 2021

Req # A-2020-000460

Adverse Drug Reaction (ADR) for botulinum toxin brand name. Report number: E2B_03068655.

Organization: Health Canada

10 page(s)
February 2021

Req # A-2020-000539

Adverse Reaction Reports (AERs) for INSULIN GLARGINE. Report numbers: 730858, 732799, 733584, 734304.

Organization: Health Canada

16 page(s)
February 2021

Req # A-2020-000546

Adverse Reaction Reports (AERs) for TERIFLUNOMIDE. Report numbers: 735570, E2B_02848292, E2B_02921071.

Organization: Health Canada

25 page(s)
February 2021

Req # A-2020-000660

Adverse Reaction Reports (AERs) for DEXILANT. Report numbers: E2B_03122964, E2B_03123449, E2B_03106078.

Organization: Health Canada

69 page(s)
February 2021

Req # A-2020-000663

Adverse Reaction Reports (AERs) for VEDOLIZUMAB. Report numbers: E2B_03058557, E2B_03105558, E2B_03108821, E2B_03109369, E2B_03114409, E2B_03114936. E2B_03124462, E2B_03138211, E2B_03149549, E2B_03152074, E2B_03153521, E2B_03156764, E2B_03157176, E2B_03169866, E2B_03128024.

Organization: Health Canada

249 page(s)
February 2021

Req # A-2020-000712

Adverse Reaction Reports (AERs). Report numbers: E2B_02637979, E2B_02691221, 000733603, E2B_02722938, E2B_02775548, E2B_02879844, E2B_02899406, E2B_02899423, E2B_02928723, E2B_02931031.

Organization: Health Canada

108 page(s)
February 2021

Req # A-2020-000780

Adverse Reaction Reports (AERs). Report numbers: E2B_03005325, E2B_03170719, E2B_03170942, 000914300, E2B_02785989, 000914302 000915863.

Organization: Health Canada

160 page(s)
February 2021

Req # A-2020-000809

Adverse Reaction Reports (AERs). Report numbers: E2B_02956696, E2B_02956422, E2B_02984209, E2B_02996660, E2B_03045680, E2B_03047613.

Organization: Health Canada

90 page(s)
February 2021

Req # A-2020-000826

Adverse Drug Reaction (ADR). Report number: E2B_03233229.

Organization: Health Canada

13 page(s)
February 2021
Date modified: